ArticlePharmacogenomics
Patient comprehension of preemptive pharmacogenomic results.
Article in Pharmacogenomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPreemptive pharmacogenomic (PGx) testing is a candidate for broad implementation because of its potential to improve medication safety and outcomes. However, little is known about how patients may process preemptively generated PGx information.
methodsWe conducted a survey study in a cohort of 5,000 individuals receiving preemptive PGx testing in a primary care clinic in the USA. We assessed patients' perceived understanding of results and confidence in current prescription drugs and doses before and after they received PGx information.
results4,624 individuals completed the pre-results survey (92.8% survey completion rate), and 3,408 (74.4% of pre-results survey completers) completed the post-results survey. Participants currently taking prescription medications were more likely to report inability to understand their PGx results. Additionally, participants' confidence in their current prescription drugs and drug doses declined following receipt of PGx results, and this decline was associated with number of prescriptions and perceived understanding of PGx results. Health literacy and educational attainment were not associated with reduced confidence.
conclusionAs preemptive PGx testing is considered for implementation in primary care settings, care must be taken to support patients with preexisting prescriptions to ensure adequate understanding of the immediate relevancy and actionability of PGx results in their healthcare.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.